Norbert Bischofberger - May 30, 2025 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
Director
Signature
/s/ Vanina de Verneuil, Attorney-In-Fact
Stock symbol
VIR
Transactions as of
May 30, 2025
Transactions value $
$0
Form type
4
Date filed
6/2/2025, 07:17 PM
Previous filing
Aug 20, 2024
Next filing
Jun 6, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BISCHOFBERGER NORBERT W Director C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET , SUITE 900, SAN FRANCISCO /s/ Vanina de Verneuil, Attorney-In-Fact 2025-06-02 0001190273

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $0 +8K +50% $0.00 24K May 30, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Award $0 +16K $0.00 16K May 30, 2025 Common Stock 16K $4.94 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
F2 The RSUs will vest in full on May 30, 2026.
F3 The shares subject to the stock option will vest and become exercisable in full on May 30, 2026.